Web Analytics

3 Latest Announced Rounds

  • $3,500,000
    Seed

    1 Investors

    Technology, Information and Internet
    Dec 20th, 2024
  • $5,619,170
    Series B

    1 Investors

    Research Services
    Dec 20th, 2024
  • $8,000,000
    Unknown

    5 Investors

    Computer & Network Security
    Dec 20th, 2024
$671.88M Raised in 44 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Odimma Therapeutics

start up
France - ILLKIRCH GRAFFENSTADEN, Grandest
  • 04/05/2023
  • Seed
  • $2,213,210

Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy.

Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients.

Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique.

By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has designed a next-generation personalized immunization platform that brings a sustainable therapeutic solution to fight the most hard-to-treat cancers.

Carried by a team of experts and a supportive environment, we are now preparing our upcoming entry in the clinic


Related People

Jessica MattaCo Founder

Jessica Matta France - Strasbourg, Grand Est

Always passionate about the biological mechanisms involved in the anti-tumor response, I deeply believe in the future of personalized medicine. I co-founded Odimma in 2017, with Dr Jean-Marc Limacher, in order to develop novel immunotherapy strategies based on what makes each patient unique.

With a significant scientific and industrial background in human immunobiology and cancer immunotherapy, I developed my expertise in translational drug development as well as communication and management skills. As CEO of Odimma, my professional commitment is now to ensure the operational and financial management of the company, as well as the scientific coordination of projects, in order to provide a tailored treatment with a favourable economic profile both for the companies producing it and for the healthcare systems using it.

My most beautiful mission: Translating patient uniqueness into unique patient treatments!